Press Release | November 19, 2026
Ansa Biotechnologies Raises $71.5 Million in Oversubscribed Series C Round to Scale Guaranteed DNA Synthesis
Read More
Press Release | November 16, 2026
GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic
Read More
Press Release | November 10, 2026
Vittoria Biotherapeutics Announces FDA RMAT and Orphan Drug Designations for Senza5 CART5 (VIPER-101) in T-Cell Lymphoma
Read More
Press Release | October 22, 2026
Sundance Biosciences Announces First Patient Dosed in U.S. Phase 2 Clinical Trial of SUN-627 for Progressive Forms of Multiple Sclerosis (MS)
Read More